SCHEMBL19970495

SCHEMBL19970495

COC[C@H]1OC2(C=C(C(=O)O)C(S(=O)(=O)Cc3ccc(F)cc3Cl)CC2)O[C@@H]1COC

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.34
PKM P14618 1/20 0.34
CYP2C19 P33261 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 2/20 0.33
TLR4 O00206 4/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
HTR2A P28223 2/20 0.32
P2RX7 Q99572 2/20 0.32
HSD11B1 P28845 1/20 0.32
P2RX4 Q99571 1/20 0.32
EPHX2 P34913 1/20 0.32
MEN1 O00255 1/20 0.32
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970494 0.91 ALDH1A1 (0.34) CYP2D6PKMCYP2C19MAPTALDH1A1
SCHEMBL20111174 0.90 TLR4 (0.43) CYP2D6PKMCYP2C19MAPTTHRB
SCHEMBL19970535 0.89 ALDH1A1 (0.37) CYP2D6PKMCYP2C19MAPTALDH1A1
SCHEMBL19970497 0.89 ALDH1A1 (0.37) CYP2D6PKMCYP2C19MAPTALDH1A1
SCHEMBL19970490 0.88 ALDH1A1 (0.32) CYP2D6PKMCYP2C19ALDH1A1GAA
SCHEMBL19970499 0.88 KMT2A (0.37) CYP2D6PKMCYP2C19MAPTALDH1A1
Trifluoroacetic Acid SCHEMBL19970480 0.85 ALDH1A1 (0.30) ALDH1A1GAAP2RX4
SCHEMBL19970529 0.84 MAPT (0.34) CYP2D6PKMCYP2C19MAPTALDH1A1
SCHEMBL4149935 0.83 TLR4 (0.51) KMT2ATLR4PSEN1PSEN2APH1B
SCHEMBL4153029 0.83 TLR4 (0.51) KMT2ATLR4PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118708-A1 CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-03 US disclosed
EP-3296296-A1 CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118708-A1 CYCLIC COMPOUND TLR4, TLR3, TLR9 CYP2D6 3591/4885PKM 2747/4885CYP2C19 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.